Venn Life Sciences Holdings PLC Grant of Share Option & Total Voting Rights (2831E)
November 03 2015 - 1:00AM
UK Regulatory
TIDMVENN
RNS Number : 2831E
Venn Life Sciences Holdings PLC
03 November 2015
3 November 2015
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Grant of Share Option
& Total Voting Rights
Venn Life Sciences (AIM: VENN), a growing Clinical Research
Organisation (CRO) providing clinical trial management and
resourcing solutions to pharmaceutical, biotechnology and medical
device clients, announces that it has granted an option over
770,000 ordinary shares, representing 1.28% of the current issued
share capital of the Company, to Jonathan Hartshorn, Chief
Financial Officer.
The shares have an exercise price of 23p, and an exercise period
from 3 November 2018 to 2 November 2025.
Following this grant the Company has granted options over
3,640,000 ordinary representing 6.04% of the current issued share
capital.
Total Voting Rights
The Company's issued share capital consists of 60,239,263
ordinary shares. There are no ordinary shares held in treasury.
Therefore, in accordance with the FCA's Disclosure and Transparency
Rule 5.6.1, the Company confirms that the total number of voting
rights in the Company are 60,239,263.
Enquiries:
Venn Life Sciences Holdings www.vennlifesciences.com
Plc
Tony Richardson, Chief Executive Tel: +353 154 99 341
Officer
Jonathan Hartshorn, Chief Tel: +353 153 93 269
Financial Officer
Orla McGuinness, Marketing Tel: +353 153 93 269
Manager
Zeus Capital (Nominated Adviser
and Co-Broker)
Andrew Jones/Phil Walker Tel: 0161 831 1512
Dominic Wilson/Alex Davies Tel : 020 3829 5000
Hybridan LLP (Co-Broker)
Claire Louise Noyce Tel: 020 3764 2341
Walbrook PR Ltd Tel: 020 7933 8787 or venn@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
About Venn Life Sciences Limited:
Venn is a full service European Contract Research Organisation
providing clinical trial management and resourcing solutions to
pharmaceutical, biotechnology and medical device organisations.
With dedicated operations in France, Germany, the Netherlands, the
UK, Ireland and Europe wide representation, Venn specialises in
both national and European-wide Phase II-Phase IV multi-site trials
with extensive expertise in EU regulations, therapeutic areas and
local languages. Over a 25 year history, Venn has built up
substantial study experience, contributing to the efficient
management of sites, budgets and communication channels with all
parties involved. Venn also has an innovation division - Innovenn -
focused primarily on breakthrough development opportunities in Skin
Science. In October 2015 Venn completed the acquisition of Kinesis
Pharma BV, highly differentiating Venn within the CRO market as it
can now offer services from early clinical/non-clinical evaluation
through to Phase IV. This deepens its service capability and
enables Venn to offer a complete end-to-end service.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUUVNRVNAARAA
(END) Dow Jones Newswires
November 03, 2015 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024